fda semaglutide shortage resolved february 2025 announcement 🚨 Ends The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This signals a significant Semaglutide Shortage Ends: Compounded Versions

Precision Medicine: Biomarkers to Predict Responders A striking feature of the SUSTAIN and STEP programs is the broad dispersion of individual outcomes: some participants lose more than 20% of their initial body weight, whereas others achieve only modest reductions despite identical dosing and adherence

T 3 toxicosis occurs in about 5% of patients with thyrotoxicosis, more commonly in toxic multinodular goiter

GLP-1 medications like semaglutide slow down digestion, which is the main source of the discomfort that people can experience

Patients who have lost 10-15 lbs in the first 6 weeks and still have 50-80+ lbs to lose are facing a 2-4 year medication commitment at escalating doses, with zero guarantee of sustained results if stopped

1 mM ATP

Semaglutide counterfeits flooded the market within months of Wegovy approval